Abstract
The pyrrolo[2,3-d]pyrimidine nucleus is a deaza-isostere of adenine, the nitrogenous base of ATP, and is present in many ATP-competitive inhibitors of different kinases. In the last few years the number of articles and patents that have appeared involving this type of inhibitors has dramatically increased and some compounds have been approved for the treatment of inflammatory or myeloproliferative diseases. Other derivatives are currently being evaluated in clinical trials. This review deals with pyrrolo[2,3- d]pyrimidine derivatives active as kinase inhibitors that have been reported in the literature from 2011 to 2016, with a particular interest on the recently patented compounds. The molecules are classified depending on the inhibited kinase, focusing on their chemical structures.
Keywords: Pyrrolo[2, 3-d]pyrimidine, kinase inhibitors, patents, anticancer agents, anti-inflammatory agents.
Current Medicinal Chemistry
Title:Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors
Volume: 24 Issue: 19
Author(s): Francesca Musumeci, Monica Sanna, Giancarlo Grossi, Chiara Brullo, Anna Lucia Fallacara and Silvia Schenone*
Affiliation:
- Dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Viale Benedetto XV, 3, I-16132, Genova,Italy
Keywords: Pyrrolo[2, 3-d]pyrimidine, kinase inhibitors, patents, anticancer agents, anti-inflammatory agents.
Abstract: The pyrrolo[2,3-d]pyrimidine nucleus is a deaza-isostere of adenine, the nitrogenous base of ATP, and is present in many ATP-competitive inhibitors of different kinases. In the last few years the number of articles and patents that have appeared involving this type of inhibitors has dramatically increased and some compounds have been approved for the treatment of inflammatory or myeloproliferative diseases. Other derivatives are currently being evaluated in clinical trials. This review deals with pyrrolo[2,3- d]pyrimidine derivatives active as kinase inhibitors that have been reported in the literature from 2011 to 2016, with a particular interest on the recently patented compounds. The molecules are classified depending on the inhibited kinase, focusing on their chemical structures.
Export Options
About this article
Cite this article as:
Musumeci Francesca , Sanna Monica , Grossi Giancarlo , Brullo Chiara, Fallacara Lucia Anna and Schenone Silvia *, Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors, Current Medicinal Chemistry 2017; 24 (19) . https://dx.doi.org/10.2174/0929867324666170303162100
DOI https://dx.doi.org/10.2174/0929867324666170303162100 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
3D QSAR Pharmacophore Modeling for c-Met Kinase Inhibitors
Medicinal Chemistry Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Emerging Hsp90 Inhibitors: From Discovery to Clinic
Anti-Cancer Agents in Medicinal Chemistry The Progress of the Anticancer Agents Related to the Microtubules Target
Mini-Reviews in Medicinal Chemistry Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119
Current Radiopharmaceuticals Intracellular Calcium Homeostasis and Kidney Disease
Current Medicinal Chemistry Functional Genomic Approaches Targeting the Wnt Signaling Network
Current Drug Targets Molecular Pathology and Molecular Markers of Ductal Carcinoma in-situ
Current Cancer Therapy Reviews Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy A Novel Small Molecule Inhibitor of FAK and IGF-1R Protein Interactions Decreases Growth of Human Esophageal Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Determination of Binding Potency of Peptidic Inhibitors of Grb2-SH2 by Using the Protein-Captured Biosensor Method
Protein & Peptide Letters Synergic Study of α-Glucosidase Inhibitory Action of Aloin and its Antioxidant Activity with and without Camel β-Casein and its Peptides
Protein & Peptide Letters Comparative Account of Quality Management and Regulatory Aspects of Products with Health Claims: Existing Approaches and Future Challenges for Probiotics and Herbal Products
Applied Clinical Research, Clinical Trials and Regulatory Affairs Anticancer Potential of Calli <i>Versus</i> Seedling Extracts Derived from <i>Rosmarinus officinalis</i> and <i>Coleus hybridus</i>
Current Pharmaceutical Biotechnology Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design Novel Kynurenic Acid Analogues in the Treatment of Migraine and Neurodegenerative Disorders: Preclinical Studies and Pharmaceutical Design
Current Pharmaceutical Design Polymer Membrane and Cell Models for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Kinase Phosphorylation-based Mechanisms of PARP Inhibitor Resistance During Synthetic Lethal Oncotherapy
Current Signal Transduction Therapy